**Supplemental data**

**Supplemental table S1: Primer sequences of target genes.**

|  |  |
| --- | --- |
| **Target gene** | **Sequence 5' - 3'** |
| ***SERPINC1 for*** | CCAGGACATCAGTGAGTTGGT |
| ***SERPINC1 re*** | GCTCTGGATTGCTCTGCATT |
| ***PROC for*** | GCTCATTGATGGGAAGATGAC |
| ***PROC rev*** | AGGGGTGGATGAGCACTG |
| ***PROS1 for*** | ACATACCTGGGTGGCCTTC |
| ***PROS1 rev*** | TCCAGATCCAACTGTACACCAT |
| ***F2 for*** | GCAACCTGGAGCGAGAGT |
| ***F2 rev*** | TTGGCCCAGAACACATCC |
| ***F7 for*** | CAGCTCCAGTCCTATATCTGCTTC |
| ***F7 rev*** | CAGCTGGTCATCCTTGTGC |
| ***F8 for*** | AAAGCTCGACTTCACCTCCA |
| ***F8 rev*** | ACTTGCAGCCACTCTTTTGG |
| ***F9 for*** | TTTGAAAACACTGAAAGAACAACTG |
| ***F9 rev*** | CATGGATTGGACTCACACTGA |
| ***Rps13 for*** | CCCCACTTGGTTGAAGTTGA |
| ***Rps13 rev*** | ACACCATGTGAATCTCTCAGGA |

**Supplemental table S2: Clinical characteristics and laboratory results of study participants with and without increased liver fat content.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Controls (N=66)** | **Fatty liver (N=60)** | **p-value** |
| **Sex (m/w, n)** | 28/38 | 24/36 | ns |
| **Age (years)** | 61 (53 – 66) | 56 (52 – 63) | ns |
| **Body weight (kg)** | 76 (65 – 88) | 93 (82 – 109) | <0.0001 |
| **Body-Mass-Index (kg/m2)** | 27 (24 – 31) | 32 (28 – 37) | <0.0001 |
| **C-reactive protein (mg/dl)** | 0.07 (0.07 – 0.19) | 0.23 (0.10 – 0.51) | <0.0001 |
| **Creatinine (mg/dl)** | 0.8 (0.6 – 0.9) | 0.8 (0.7 – 0.9) | ns |
| **ALT (U/l)** | 24 (19 – 30) | 31 (23 – 48) | <0.0001 |
| **Glycated hemoglobin (HbA1c, mmol/mol)** | 40 (37 – 42) | 41 (38 – 43) | 0.0406 |
| **Fasting glucose (mg/dl)** | 5.8 (5.6 – 6.1) | 6.0 (5.7 – 6.4) | 0.0159 |
| **OGTT-derived insulin sensitivity** | 11.9 (7.1 – 18.0) | 6.5 (4.3 – 8.9) | <0.0001 |
| **Total adipose tissue (TAT, l)** | 27.4 (20.9 – 37.4) | 41.9 (31.6 – 51.9) | <0.0001 |
| **Visceral adipose tissue (VAT, l)** | 4.0 (2.4 – 5.3) | 5.4 (4.0 – 7.4) | <0.0001 |
| **Subcutaneous adipose tissue (SCAT, l)** | 8.7 (6.8 – 13.5) | 15.2 (10.9 – 20.2) | <0.0001 |
| **Liver fat content (%)** | 2.8 (1.6 – 3.8) | 12.1 (8.5 – 18.7) | <0.0001 |

Shown are results as median and interquartile range (1st – 3rd).

Abbreviations: ALT: alanine amino transferase; OGTT: oral glucose tolerance test; ns: not significant.

**Supplemental table S3: LOINC codes of the investigated parameters in the study.** LOINC (Logical Observation Identifier Names and Codes) is a code system for the universal identification of laboratory parameters and other clinical measurements initiated by the Regenstrief Institute#.

|  |  |
| --- | --- |
| **Parameter** | **LOINC code** |
| Sex (w/m, n) | 46098-0 |
| Age (years) | 30525-0 |
| Body weight (kg) | 29463-7 |
| Body-Mass-Index (kg/m2) | 39156-5 |
| Fasting glucose (mg/dl) | 1558-6 |
| OGTT-derived insulin sensitivity | 93792-0 |
| Glycated hemoglobin (HbA1c, mmol/mol) | 4548-4 |
| C-reactive protein (mg/dl) | 1988-5 |
| Creatinine (mg/dl) | 2160-0 |
| ALT (U/l) | 1742-6 |
| AST (U/l) | 1920-8 |
| aPTT (sec) | 3173-2 |
| Fibrinogen (mg/dl) | 3255-7 |
| D-Dimer (µg/ml FEU) | 71427-9 |
| Factor VII (%) | 3198-9 |
| Factor VIII (%) | 3209-4 |
| Factor IX (%) | 3187-2 |
| Antithrombin (%) | 27811-9 |
| Protein C (%) | 27818-4 |
| Protein S (%) | 27821-8 |

# Copyright © 2020 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.